Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Esiti a lungo termine delle infusioni di lidocaina per la prova del dolore post-operatorio (LOLIPOP). (LOLIPOP)

8 novembre 2026 aggiornato da: Prof Tomas Corcoran, Monash University

The LOLIPOP Trial is a large (n=4,300 patients) pragmatic, international, multicentre, prospective, randomised, double blind, placebo-controlled, parallel assessment, safety and effectiveness superiority study.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The Trial's purpose is to evaluate the effectiveness of lidocaine infusions commenced during surgery and extending up to 24 hours postoperatively, on the incidence of moderate or severe chronic post-surgical pain (CPSP) detected one year following surgery in female patients undergoing elective breast cancer surgery. The trial has 90% power to detect a clinically meaningful (25%) reduction in the incidence of the primary outcome. Secondary outcomes include safety events, analgesic efficacy (pain scores and opioid consumption), neuropathic characteristics of CPSP, and psychological and quality of life outcomes.

Tipo di studio

Interventistico

Iscrizione (Stimato)

4300

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • New South Wales
      • Kingswood, New South Wales, Australia, 2747
        • Reclutamento
        • Nepean Hospital
      • Mount Druitt, New South Wales, Australia, 2770
        • Reclutamento
        • Blacktown Mount Druitt Hospital
      • Sydney, New South Wales, Australia, 2217
        • Reclutamento
        • St George Hospital
      • Sydney, New South Wales, Australia, 2145
        • Completato
        • Westmead Hospital
      • Sydney, New South Wales, Australia, 2035
        • Reclutamento
        • Royal North Shore Hospital
    • Queensland
      • Brisbane, Queensland, Australia, 4029
        • Completato
        • Royal Brisbane and Women's Hospital
      • Coopers Plains, Queensland, Australia, 4108
        • Attivo, non reclutante
        • Queen Elizabeth II Jubilee Hospital
      • Mackay, Queensland, Australia, 4740
        • Attivo, non reclutante
        • Mackay Base Hospital
      • Rockhampton, Queensland, Australia, 4700
        • Completato
        • Rockhampton Hospital
      • Southport, Queensland, Australia, 4215
        • Completato
        • Gold Coast Hospital and Health Service- Gold Coast University Hospital
      • Woolloongabba, Queensland, Australia, 4102
        • Reclutamento
        • Princess Alexandra Hospital
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Reclutamento
        • Flinders Medical Centre
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
        • Reclutamento
        • Royal Hobart Hospital
    • Victoria
      • Ballarat, Victoria, Australia, 3350
        • Completato
        • Anaesthetic Group Ballarat
      • Ballarat, Victoria, Australia, 3350
        • Attivo, non reclutante
        • Ballarat Health Services (Grampians Health)
      • Geelong, Victoria, Australia, 3220
        • Reclutamento
        • Barwon Health - University Hospital Geelong
      • Melbourne, Victoria, Australia, 3065
        • Reclutamento
        • St Vincent's Hospital Melbourne
      • Melbourne, Victoria, Australia, 3004
        • Reclutamento
        • The Alfred
      • Melbourne, Victoria, Australia, 3050
        • Attivo, non reclutante
        • Royal Melbourne Hospital
      • Melbourne, Victoria, Australia, 3165
        • Completato
        • Monash Health - Moorabbin Hospital
      • Melbourne, Victoria, Australia, 3076
        • Ritirato
        • Northern Hospital
      • Ringwood East, Victoria, Australia, 3135
        • Reclutamento
        • Maroondah Hospital - Eastern Health
      • Shepparton, Victoria, Australia, 3630
        • Completato
        • Goulburn Valley Health
      • Traralgon, Victoria, Australia, 3844
        • Ritirato
        • Latrobe Regional Hospital
    • Western Australia
      • Bentley, Western Australia, Australia, 6102
        • Reclutamento
        • Bentley Health Service
      • Perth, Western Australia, Australia, 6000
        • Reclutamento
        • Royal Perth Hospital
      • Perth, Western Australia, Australia, 6008
        • Reclutamento
        • St John of God Subiaco
      • Chai Wan, Hong Kong
        • Reclutamento
        • Pamela Youde Nethersole Eastern Hospital
      • Wan Chai, Hong Kong
        • Reclutamento
        • Ruttonjee Hospital
    • Sha Tin
      • Shatin, Sha Tin, Hong Kong
        • Reclutamento
        • North District Hospital
    • Auckland
      • Auckland, Auckland, Nuova Zelanda, 1023
        • Reclutamento
        • Auckland City Hospital
    • Middlemore
      • Auckland, Middlemore, Nuova Zelanda, 2025
        • Reclutamento
        • Middlemore Hospital
    • Waikato Region
      • Hamilton, Waikato Region, Nuova Zelanda, 3204
        • Reclutamento
        • Waikato Hospital
      • Belfast, Regno Unito, BT9 7AB
        • Reclutamento
        • Belfast City Hospital
      • Bristol, Regno Unito, BS10 5NB
        • Reclutamento
        • Southmead Hospital, North Bristol Trust
      • Darlington, Regno Unito, DL3 6HX
        • Terminato
        • Darlington Memorial Hospital
      • Dudley, Regno Unito, DY1 2HQ
        • Reclutamento
        • Russells Hall Hospital
      • Liverpool, Regno Unito
        • Reclutamento
        • Royal Liverpool and Broadgreen Hospitals
      • London, Regno Unito, N19 5NF
        • Reclutamento
        • Whittington Hospital
      • London, Regno Unito
        • Reclutamento
        • Royal Marsden Hospital - London and Sutton
      • Newcastle upon Tyne, Regno Unito
        • Reclutamento
        • Newcastle upon Tyne Hospitals
      • Norwich, Regno Unito, NR4 7UY
        • Reclutamento
        • Norfolk and Norwich University Hospital
      • Rotherham, Regno Unito, S60 2UD
        • Reclutamento
        • Rotherham NHS Foundation Trust
      • Sheffield, Regno Unito, S10 2JF
        • Reclutamento
        • Royal Hallamshire Hospital
      • Southampton, Regno Unito
        • Reclutamento
        • University Hospital Southampton
      • St Helens, Regno Unito, WA9 3DA
        • Reclutamento
        • St Helen's Hospital
      • Torquay, Regno Unito, TQ2 7AA
        • Attivo, non reclutante
        • Torbay Hospital
      • Winchester, Regno Unito, SO22 5DG
        • Reclutamento
        • Royal Hampshire County Hospital
    • Scotland
      • Wishaw, Scotland, Regno Unito
        • Reclutamento
        • University Hospital Wishaw

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Consenting adult female patients (≥18 years) undergoing mastectomy (unilateral or bilateral) or breast conserving surgery (unilateral or bilateral) for the primary excision of confirmed or suspected primary breast cancer under general anaesthesia (including those with simultaneous insertion of tissue expanders or implants)*. * this specifically excludes patients undergoing surgery for locoregional recurrence
  • American Society of Anaesthesiologist (ASA) physical scale 1-3

Exclusion Criteria:

  • Mastectomy or breast conserving surgery with add on procedures e.g laparoscopic salpingectomy
  • Where surgery is being performed for locoregional recurrence of breast cancer
  • Pre-existing pain at site of surgery, axilla, ipsilateral side of chest wall or the ipsilateral upper arm (at diagnosis prior to any tumor locating procedures)
  • Re-excision procedures where the margins at the index surgery have been deemed insufficient
  • When immediate autologous reconstruction surgery is planned
  • Where delayed autologous reconstruction surgery on the operative breast within one year is planned
  • Planned use of regional analgesia infusions
  • Impaired cognition
  • Pregnant or lactating females
  • Transgender patients
  • Known metastatic disease
  • History of anaphylaxis, sensitivity or known contraindication to lidocaine (or other amide local anaesthetic agents e.g. other amide local anaesthetic agents: ropivacaine, bupivacaine, mepivacaine, prilocaine, etidocaine), including patients with porphyria or methaemoglobinaemia
  • History of epilepsy
  • Baseline heart rate < 50 bpm or systolic blood pressure < 100mmHg.
  • Acute coronary event in the last three months
  • Cardiac conduction abnormalities, including; Atrial fibrillation, Heart block (all degrees), Bundle Branch Block or Fascicular block, Prolonged QT interval, Wolf Parkinson White syndrome, channelopathy such as Brugada syndrome. A preoperative Electrocardiogram (ECG) is not mandatory, unless clinically indicated
  • Abnormal serum potassium concentration (based upon site laboratory reference ranges)
  • Active liver disease e.g. viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, haemochromatosis, other rarer causes)
  • Medications within the last 7 days which are known / suspected to slow lidocaine metabolism (amiodarone, beta blockers, cimetidine, fluoroquinolones, fluvoxamine, imidazoles, macrolides, verapamil, HIV drugs)
  • Cardiac Failure (any documented heart failure at peroperative assessment or GP records)
  • Severe Renal Failure (Creatinine Clearance of less than 30ml/min or dialysis dependent)
  • Co-administration of lidocaine within 24 hours prior to surgery for other reasons (e.g. lidocaine patches

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Lidocaine

2% Lidocaine infusion intra-operative and 10% Lidocaine infusion post-operative.

Lidocaine infusion:

  1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).*

  2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).*

  3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.

    • *Day-case surgery receives intraoperative bolus and intraoperative infusion only
Altri nomi:
  • Xylocaina (lidocaina) 2% e Xylocard (lidocaina) 10%
Comparatore placebo: Placebo

0.9% Saline infusion intra-operative and 0.9% Saline infusion post-operative.

Placebo infusion:

  1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 0.9% Saline solution.*

  2. Followed by a 0.9% Saline solution intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).*

  3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 0.9% Saline solution infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.

    • *Day-case surgery receives intraoperative bolus and intraoperative infusion only
Altri nomi:
  • Soluzione salina allo 0,9%.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The incidence of moderate or severe CPSP at 1 year after surgery, as reported by the patient at the follow-up review.
Lasso di tempo: 1 year post-surgery

Numerical rating scale ≥4 out of 10 for worst pain in the last week - The pain must have been present for at least 3 months prior to the one year assessment (or longer).

1 year post-surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
The incidence of severe CPSP at 1 year after surgery
Lasso di tempo: 1 year post surgery

NRS for worst pain the in the last week of ≥7)

1 year post surgery
Severity of pain at the site of surgery
Lasso di tempo: 1 year post surgery

Assessed using "average" and "worst" NRS pain score in the last week, obtained from the adapted modified Brief Pain Inventory-Short Form (mBPI-SF)

1 year post surgery
Incidence of neuropathic symptoms
Lasso di tempo: 1 year post surgery

Incidence examined as a binary outcome using the Short Form of Douleur Neuropathique 4 Questions (S-DN4)

1 year post surgery
Physical functioning
Lasso di tempo: 1 year post surgery

Using interference component of mBPI-SF

1 year post surgery
Changes in quality of life metrics EuroQol 5 Dimension 5 Level (EQ-5D-5L) at 1 year after surgery compared to baseline
Lasso di tempo: 1 year post surgery

Changes in the quality of life

1 year post surgery
Changes in psychological wellbeing Kessler Psychological Distress Scale (K-10) at 1 year after surgery compared to baseline.
Lasso di tempo: 1 year post surgery

Changes in psychological wellbeing

1 year post surgery
The incidence of mild or greater pain at the site of surgery at 1 year after surgery
Lasso di tempo: 1 year post surgery

NRS for worst pain the in the last week of ≥1

1 year post surgery
The incidence of discomfort or altered sensation at the site of surgery (not reported as pain)
Lasso di tempo: 1 year post surgery

Patients asked if they have any altered sensation at the site of surgery

1 year post surgery
Severity of acute postoperative pain at rest
Lasso di tempo: 24 hours postoperatively

Maximum pain score, Numerical rating scale (NRS) 0-10

24 hours postoperatively
Severity of Acute postoperative pain on movement
Lasso di tempo: 24 hours postoperatively

Maximum pain score, Numerical rating scale (NRS) 0-10

24 hours postoperatively
Postoperative opioid consumption
Lasso di tempo: on Day 1

Morphine Equivalent Opioid Consumption (MEQ)

on Day 1
Postoperative opioid consumption
Lasso di tempo: 3 months (last 24-hours)

Morphine Equivalent Opioid Consumption (MEQ)

3 months (last 24-hours)
Postoperative opioid consumption
Lasso di tempo: 1 year post surgery (last 24 hours)

Morphine Equivalent Opioid Consumption (MEQ)

1 year post surgery (last 24 hours)
The incidence of mortality at 1 year
Lasso di tempo: 1 year post surgery

Mortality at 1 year

1 year post surgery
UK NHS costs of care over 1 year following surgery
Lasso di tempo: 1 year post surgery

UK/NHS sites only

1 year post surgery
Productivity costs over 1 year following surgery
Lasso di tempo: 1 year post surgery

UK/NHS sites only

1 year post surgery
Quality-adjusted life years (QALYs) over 1 year following surgery
Lasso di tempo: 1 year post surgery

UK/NHS sites only

1 year post surgery
Cost-effectiveness of perioperative lidocaine infusions compared to usual care, from a primary UK NHS perspective and broader perspective including productivity, at 1 year.
Lasso di tempo: 1 year post surgery

UK/NHS sites only

1 year post surgery

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of treated bradycardia intraoperatively
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of treated hypotension intraoperatively
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of treated bradycardia in Post Anaesthesia Care Unit (PACU)
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of treated hypotension in Post Anaesthesia Care Unit (PACU)
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of intraoperative infusion stopping events
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of Post Anaesthesia Care Unit (PACU) infusion stopping events
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication)

24 hours postoperatively
Incidence of postoperative infusion stopping events on the ward
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints, (x2 symptoms, x1 sign, x1 complication)

24 hours postoperatively
Incidence of suspected lidocaine toxicity events
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of suspected SEVERE lidocaine toxicity events
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints, (generalised seizure, sudden unexplained LOC, life-threatening arrhythmia, or asystole, cardiac or circulatory arrest)

24 hours postoperatively
Incidence of Medical Emergency Team (MET) activation
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of unplanned Intensive Care Unit (ICU), High Dependency Unit (HDU) or Critical Care Unit (CCU) admission
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of study drug unblinding events
Lasso di tempo: 24 hours postoperatively

Drug related safety Endpoints

24 hours postoperatively
Incidence of subcutaneous catheter site events
Lasso di tempo: Day 30

Drug related safety Endpoints

Day 30

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Tomas Corcoran, Royal Perth Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

27 luglio 2022

Completamento primario (Stimato)

1 maggio 2028

Completamento dello studio (Stimato)

1 maggio 2029

Date di iscrizione allo studio

Primo inviato

3 ottobre 2021

Primo inviato che soddisfa i criteri di controllo qualità

3 ottobre 2021

Primo Inserito (Effettivo)

8 ottobre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • HREC/74777/Alfred-2021

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .